全文获取类型
收费全文 | 3491篇 |
免费 | 267篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 152篇 |
妇产科学 | 116篇 |
基础医学 | 352篇 |
口腔科学 | 77篇 |
临床医学 | 340篇 |
内科学 | 860篇 |
皮肤病学 | 34篇 |
神经病学 | 266篇 |
特种医学 | 158篇 |
外国民族医学 | 1篇 |
外科学 | 440篇 |
综合类 | 73篇 |
一般理论 | 1篇 |
预防医学 | 400篇 |
眼科学 | 10篇 |
药学 | 191篇 |
中国医学 | 1篇 |
肿瘤学 | 293篇 |
出版年
2021年 | 39篇 |
2019年 | 43篇 |
2018年 | 48篇 |
2017年 | 33篇 |
2016年 | 36篇 |
2015年 | 30篇 |
2014年 | 85篇 |
2013年 | 108篇 |
2012年 | 171篇 |
2011年 | 161篇 |
2010年 | 104篇 |
2009年 | 87篇 |
2008年 | 128篇 |
2007年 | 187篇 |
2006年 | 178篇 |
2005年 | 170篇 |
2004年 | 144篇 |
2003年 | 138篇 |
2002年 | 114篇 |
2001年 | 101篇 |
2000年 | 120篇 |
1999年 | 102篇 |
1998年 | 56篇 |
1997年 | 43篇 |
1996年 | 38篇 |
1995年 | 42篇 |
1994年 | 30篇 |
1992年 | 75篇 |
1991年 | 72篇 |
1990年 | 56篇 |
1989年 | 63篇 |
1988年 | 74篇 |
1987年 | 59篇 |
1986年 | 56篇 |
1985年 | 44篇 |
1984年 | 51篇 |
1981年 | 29篇 |
1980年 | 35篇 |
1979年 | 28篇 |
1978年 | 43篇 |
1977年 | 29篇 |
1975年 | 29篇 |
1974年 | 44篇 |
1973年 | 30篇 |
1972年 | 31篇 |
1970年 | 48篇 |
1969年 | 34篇 |
1968年 | 34篇 |
1967年 | 31篇 |
1966年 | 34篇 |
排序方式: 共有3781条查询结果,搜索用时 843 毫秒
131.
132.
Peter Stein Jolene K. Berg Linda Morrow David Polidori Eunice Artis Sarah Rusch Nicole Vaccaro Damayanthi Devineni 《Metabolism: clinical and experimental》2014
Objective
Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved for treating patients with type 2 diabetes. This study evaluated renal and non-renal effects of canagliflozin on postprandial plasma glucose (PG) excursion in patients with type 2 diabetes inadequately controlled with metformin.Materials/Methods
Patients (N = 37) were randomized to a four-period crossover study with 3-day inpatient stays in each period and 2-week wash-outs between periods. Patients received Treatments (A) placebo/placebo, (B) canagliflozin 300 mg/placebo, (C) canagliflozin 300 mg/canagliflozin 300 mg, or (D) canagliflozin 300 mg/canagliflozin 150 mg on Day 2/Day 3 in one of four treatment sequences (similar urinary glucose excretion [UGE] expected for Treatments B–D). A mixed-meal tolerance test (MMTT) was given 20 minutes post-dose on Day 3 of each period.Results
A single dose of canagliflozin 300 mg reduced both fasting and postprandial PG compared with placebo, with generally similar effects on fasting PG and UGE observed for Treatments B–D. An additional dose of canagliflozin 300 mg (Treatment C), but not 150 mg (Treatment D), prior to the MMTT on Day 3 provided greater postprandial PG reduction versus placebo (difference in incremental glucose AUC0–2h, − 7.5% for B vs A; − 18.5% for C vs A; − 12.0% [P = 0.012] for C vs B), leading to modestly greater reductions in total glucose AUC0–2h with Treatment C versus Treatment B or D. Canagliflozin was generally well tolerated.Conclusions
These findings suggest that a non-renal mechanism (ie, beyond UGE) contributes to glucose lowering for canagliflozin 300 mg, but not 150 mg. 相似文献133.
Liberman Justin S. D’Agostino McGowan Lucy Greevy Robert A. Morrow James A. Griffin Marie R. Roumie Christianne L. Grijalva Carlos G. 《Clinical rheumatology》2020,39(6):1793-1802
Clinical Rheumatology - Patients with rheumatoid arthritis (RA) often receive opioid analgesics for pain management. We examined the association between mental health conditions and the risk of... 相似文献
134.
Kathleen M. Morrow Kristen Underhill Jacob J. van den Berg Sara Vargas Rochelle K. Rosen David F. Katz 《Archives of sexual behavior》2014,43(7):1459-1467
Research has demonstrated that certain vaginal gel products—microbicides containing antiretroviral drugs—may reduce HIV infection risk among women. But for vaginal gels to avert HIV and other sexually transmitted infections (STIs), at-risk women must be willing to use them as directed. These products must therefore be “acceptable” to women and an important component of acceptability is users’ perception that the product will work to prevent infection. We sought to understand how women’s perceptions of vaginal gel properties may shape their understanding of product efficacy for HIV and STI prevention. Sixteen women completed two in-depth qualitative interviews (k = 32) to identify the range and types of sensory perceptions they experienced when using two vaginal gels. We identified emergent themes and linkages between users’ sensory perceptions and their beliefs about product efficacy. Users’ predictions about product efficacy for preventing infection corresponded to measurable physical properties, including gel volume, location in the vagina, coating behavior, sensation of the gel in the vagina, leakage, and gel changes during coital acts. Although the women described similar sensory experiences (e.g., gel leaked from the vagina), they interpreted these experiences to have varying implications for product efficacy (e.g., leakage was predicted to increase or decrease efficacy). To improve microbicide acceptability, gel developers should investigate and deliberately incorporate properties that influence users’ perceptions of efficacy. When a microbicide is approved for use, providers should educate users to anticipate and understand their sensory experiences; improving users’ experience can maximize adherence and product effectiveness. 相似文献
135.
Jian Yan Daniel O. Villarreal Trina Racine Jaemi S. Chu Jewell N. Walters Matthew P. Morrow Amir S. Khan Niranjan Y. Sardesai J. Joseph Kim Gary P. Kobinger David B. Weiner 《Vaccine》2014
Despite an intensive vaccine program influenza infections remain a major health problem, due to the viruses’ ability to change its envelope glycoprotein hemagglutinin (HA), through shift and drift, permitting influenza to escape protection induced by current vaccines or natural immunity. Recently a new variant, H7N9, has emerged in China causing global concern. First, there have been more than 130 laboratory-confirmed human infections resulting in an alarmingly high death rate (32.3%). Second, genetic changes found in H7N9 appear to be associated with enabling avian influenza viruses to spread more effectively in mammals, thus transmitting infections on a larger scale. Currently, no vaccines or drugs are effectively able to target H7N9. Here, we report the rapid development of a synthetic consensus DNA vaccine (pH7HA) to elicit potent protective immunity against the H7N9 viruses. We show that pH7HA induces broad antibody responses that bind to divergent HAs from multiple new members of the H7N9 family. These antibody responses result in high-titer HAI against H7N9. Simultaneously, this vaccine induces potent polyfunctional effector CD4 and CD8T cell memory responses. Animals vaccinated with pH7HA are completely protected from H7N9 virus infection and any morbidity associated with lethal challenge. This study establishes that this synthetic consensus DNA vaccine represents a new tool for targeting emerging infection, and more importantly, its design, testing and development into seed stock for vaccine production in a few days in the pandemic setting has significant implications for the rapid deployment of vaccines protecting against emerging infectious diseases. 相似文献
136.
137.
138.
139.
Anaphylaxis is an acutely presenting life‐threatening medical emergency. Surveys indicate that dentists feel inadequately able to recognize and treat anaphylaxis. This paper reviews the terminology and pathophysiology of anaphylaxis, and describes the recognition and initial management of anaphylaxis for dentists. Dentists should be able to administer intramuscular adrenaline during anaphylaxis at the appropriate dose. The role of further medical care is also explained. Six cases of anaphylaxis arising from dental oral maxillofacial surgery practice are discussed. 相似文献
140.
Letícia Bojikian CALIXTRE Bruno Leonardo da Silva GRüNINGER Thais Cristina CHAVES Ana Beatriz de OLIVEIRA 《Journal of applied oral science : revista FOB》2014,22(1):15-21